Axa
CABA icon

Axa’s Cabaletta Bio CABA Stock Holding History

Axa’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-270,516
Closed -$411K – 230
2025
Q2 		$411K Buy
270,516
+439
+0.2% +$685 ﹤0.01% 1006
2025
Q1 		$374K Sell
270,077
-346
-0.1% -$737 ﹤0.01% 961
2024
Q4 		$614K Sell
270,423
-431
-0.2% -$1.51K ﹤0.01% 924
2024
Q3 		$1.28M Buy
270,854
+76
+0% +$440 ﹤0.01% 835
2024
Q2 		$2.03M Buy
270,778
+92,616
+52% +$1.14M 0.01% 748
2024
Q1 		$3.04M Buy
+178,162
New +$3.82M 0.01% 677

Other funds holding CABA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return

Axa's CABA Position: Q3 2025 in Review

Axa sold out of Cabaletta Bio (CABA) in Q3 2025, closing a stake of 270,516 shares — an estimated $411K sold.

Axa first reported a position in CABA in Q1 2024 and held it in 6 quarters. The position peaked at $3.04M in Q1 2024. 75 funds tracked by Wall St. Rank hold CABA as of Q3 2025.

  • Axa reported no remaining Cabaletta Bio position as of Q3 2025 after selling out during the quarter.
  • Axa sold 270,516 Cabaletta Bio shares in Q3 2025, an estimated $411K.
  • Axa first reported a position in Cabaletta Bio in Q1 2024 and held it in 6 quarters.
  • Axa's Cabaletta Bio position peaked at $3.04M in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.